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Cancer survival in the Spearhead Primary Care Trusts of England, 1998-2004 
 
One- and five-year relative survival estimates for cancer patients diagnosed in 
1998-2003 and resident in ‘Spearhead’ Primary Care Trusts, compared with 
those in the rest of England: 10 common cancers, by sex.  
 
 
This report presents cancer survival estimates for adult patients (aged 15-99 years at 
diagnosis) resident in the 88 ‘Spearhead’ Primary Care Trusts (PCT) in England, 
compared with those resident in the rest of England, who were diagnosed during 
1998-2003 and followed up to the end of 2004 (see technical notes 1-3). Table 1 and 
the charts give the one- and five-year age-standardised relative survival estimates 
(technical notes 4 and 5) for patients diagnosed with one of the following ten cancers: 
bladder, breast (women), cervix, colon, lung, oesophagus, ovary, prostate, rectum and 
stomach. Differences between survival for ‘Spearhead’ PCTs and the rest of England 
were tested for statistical significance; p-values are given in Table 1 (see technical 
note 6). 
 
For most of the ten cancers, over 1,000 cases a year occurred in residents of 
‘Spearhead’ PCTs. For the most frequent – cancer of the breast in women – there 
were on average 9,000 cases eligible for analysis in the ‘Spearhead’ PCT group. Even 
for the least frequent of the ten cancers examined (cancer of the oesophagus), 600 or 
more cases in ‘Spearhead’ PCTs could be included in the analysis. For these ten 
cancers, cancer survival estimates for the ‘Spearhead’ PCTs can thus be considered 
reasonably robust.  
 
Five-year age-standardised relative survival estimates for patients diagnosed with the 
four most common cancers are given in the table below. These cancers account for 
around 50 per cent of all cancers in adults. Full details are given in Table 1.  
 
Five-year relative survival estimates (%) up to 2004 for adult patients diagnosed during  
1998-2003, major cancers, ‘Spearhead’ Primary Care Trusts and the rest of England 
 
Spearhead PCTs Rest of England Difference† Cancer 
Number of 
patients 
Five-year 
relative 
survival* 
(%) 
Number of 
patients 
Five-year 
relative 
survival* 
(%) 
 
 
 
(% points) 
Breast  Women 54,019 78.2 136,340 79.8 - 1.6 
       
Colon  Men 13,828 47.1 32,813 48.3 - 1.2 
 Women 13,062 47.9 32,585 49.6 - 1.7 
       
Lung  Men 34,545 5.9 59,478 6.6 - 0.7 
 Women 23,234 7.5 36,750 7.6 - 0.1 
       
Prostate  Men 37,335 69.2 96,451 71.1 - 1.9 
    
* Age-standardised (see technical note 5) 
† See technical note 7 
 
Five-year survival for patients resident in ‘Spearhead’ PCTs was 1.6% lower than in 
the rest of England for breast cancer in women, and 1.9% lower for prostate cancer. In 
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‘Spearhead’ PCTs, five-year survival for colon cancer was 1.2% and 1.7% lower for 
men and women, respectively, than in the rest of England. Survival from lung cancer 
in both men and women was consistently low in all PCTs (6-8%), but still 0.7% lower 
among men in ‘Spearhead’ PCTs than in the rest of England.  
 
For cancer patients resident in ‘Spearhead’ PCTs, survival was significantly lower at 
one year after diagnosis for 15 of the 16 sex-cancer combinations examined; and at 
five years after diagnosis for 12 of the 16. 
  
The difference in one-year relative survival estimates between ‘Spearhead’ PCTs and 
all other PCTs ranged from -4.7% (oesophagus, men) to -0.5% (lung, women), with 
an average difference of -2.3%.  
 
The average difference in five-year relative survival between ‘Spearhead’ PCTs and 
the rest of England was -1.7%. Survival was actually higher in ‘Spearhead’ PCTs than 
in all other PCTs for cancers of the cervix and ovary, but not significantly so. The 
largest difference in five-year survival (-4.5%) was seen for bladder cancer in women. 
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Technical Notes 
 
1)  The 2010 Public Service Agreement target for life expectancy inequalities and the 
inequalities elements of the cancer and heart disease PSA targets aim to narrow the 
gap between the population as a whole and the “fifth of areas with the worst health 
and deprivation indicators”. These are the ‘Spearhead Group’ of areas. Announced on 
19 November 2004, the ‘Spearhead Group’ consists of the Local Authority areas, and 
the PCTs which map to them, that are in the bottom fifth nationally for 3 or more of 
the following measures: 
• Male life expectancy at birth 
• Female life expectancy at birth 
• Cancer mortality rate in under 75s 
• Cardiovascular disease mortality rate in under 75s 
• Index of Multiple Deprivation 2004 (Local Authority Summary), average score.  
 
The ‘Spearhead Group’ is a fixed list of 70 Local Authorities, and the 62 (formerly 
88) PCTs that map to them. It forms the focus for Government action to tackle 
inequalities in life expectancy, cancer and cardiovascular disease.  
For further details on the location of the ‘Spearhead PCTs’ please go to: 
http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_4138963 
 
2)  All adult (15-99 years) residents of England who were diagnosed during the period 
1998-2003 with one of the ten selected cancers as a first, primary, invasive, malignant 
neoplasm were eligible for inclusion in the analyses. Records of benign or in situ 
3 
tumours, or those of uncertain behaviour, were considered ineligible. Patients known 
to have had a previous invasive primary malignancy (except non-melanoma skin 
cancer) at any site at any time since 1971 were excluded. We noted a small but steady 
increase in the overall quality of the data and in the proportion of records of sufficient 
quality for inclusion in survival analyses. For more details about exclusions from 
analysis, see ref.[1,2]  
 
3) Relative survival estimates for the same 10 common cancers were published on the 
National Statistics website on 4 April 2007 [3] for patients resident in ‘Spearhead’ 
Primary Care Trusts compared with those in the rest of England, and diagnosed 
during 1996-2001 and followed up to 31 December 2003.  
 
4)  Crude survival is the proportion of the original group of cancer patients diagnosed 
in a particular period who are still alive at the specified time after diagnosis; it is 
based on all deaths, whatever their cause. By contrast, relative survival aims to 
estimate net survival, i.e. the survival of cancer patients relative to that of the general 
population from which they are drawn. It reflects the fact that some cancer patients 
will die from other causes.  Relative survival is given by the ratio of the crude 
survival and the survival that would have been expected if the cancer patients had 
experienced the same death rates by age and sex (background mortality) as the 
general population. Life tables are used to provide these measures of background 
mortality, specific for single year of age at death, for sex, and - where possible - for 
socio-economic deprivation and/or geographic region. For these analyses, it proved 
impossible to construct new life tables for the populations of the Spearhead PCTs in 
the time available. Instead, we used regional life tables that we had previously 
constructed and which are specific to each of the Government Office Regions, based 
on mortality centred on 2001. When the analyses were performed, all patients 
diagnosed during 1998-2003 had been followed up to the end of 2004. Survival up to 
one year after diagnosis could therefore be calculated using data for all patients 
diagnosed during 1998-2003. Survival from one to two years could be calculated 
using data for those diagnosed during 1998-2002; from two to three years using data 
for those diagnosed 1998-2001; from three to four years using data for those 
diagnosed 1998-2000; and from four to five years using data for those diagnosed in 
1998-1999.  The overall estimate of five-year survival was constructed from all these 
interim estimates. This is called “complete” analysis, to distinguish it from “cohort” 
analysis, in which only patients who have been followed up for at least five years can 
contribute to the estimation of five-year survival. With follow-up data available at the 
time, cohort analysis would have been restricted to patients diagnosed in 1998-99. 
 
5) Because cancer survival varies with age at diagnosis and the age distribution of 
cancer cases differs geographically, the overall (all ages) survival estimates have been 
age-standardised to improve the comparability between geographical areas and over 
time.  We used the standard weights given in Chapter 3 of the monograph Cancer 
Survival Trends [1].  
 
6) Statistical significance tests enable us to estimate the probability (p) that a 
difference in survival between two populations indicates a real difference rather than 
being due to chance. A result that would be expected to occur less than one in 20 
times by chance (p<0.05) is conventionally described as statistically significant (at the 
5% level). 
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7) The absolute difference between five-year relative survival (%) for patients 
resident in 'Spearhead' PCTs and those resident in the rest of England is given in 
percentage points; thus for breast cancer, the survival of 78.2% in 'Spearhead' PCTs is 
lower than 79.8% in the rest of England, so the difference is shown as -1.6 percentage 
points.  
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Cancer5
% % % % One year Five year One year Five year
Bladder Men 10,789     77.3 (76.5 - 78.2) 57.1 (55.6 - 58.5) 24,778 78.8 (78.3 - 79.4) 60.4 (59.5 - 61.3) -1.5 -3.3 <0.01 <0.01
Women 4,513       66.3 (64.9 - 67.8) 49.1 (47.2 - 51.0) 9,337 70.4 (69.4 - 71.4) 53.6 (52.3 - 55.0) -4.1 -4.5 <0.01 <0.01
Persons 15,302     73.9 (73.2 - 74.6) 55.0 (53.8 - 56.1) 34,115 76.4 (75.9 - 76.9) 58.6 (57.8 - 59.3) -2.5 -3.6 <0.01 <0.01
Breast Women 54,019     93.5 (92.3 -93.7) 78.2 (77.6 - 78.7) 136,340 94.2 (94.0 - 94.3) 79.8 (79.4 - 80.1) -0.7 -1.6 <0.01 <0.01
Cervix Women 5,049       81.4 (80.3 - 82.5) 63.3 (61.8 - 64.9) 8,639 82.2 (81.3  - 83.3) 62.7 (61.4 - 63.9) -0.8 +0.6 0.281 0.509
Colon Men 13,828     66.1 (65.2 - 66.9) 47.1 (45.8 - 48.5) 32,813 69.3 (68.8 - 69.8) 48.3 (47.5 - 49.1) -3.2 -1.2 <0.01 <0.01
Women 13,062     65.9 (65.0 - 66.7) 47.9 (46.7 - 49.1) 32,585 68.9 (68.4 - 69.5) 49.6 (48.9 - 50.4) -3.0 -1.7 <0.01 <0.01
Persons 26,890     65.9 (65.3 - 66.5) 47.4 (46.5 - 48.3) 65,398 69.0 (68.6 - 69.4) 48.9 (48.4 - 49.5) -3.1 -1.5 <0.01 <0.01
Lung Men 34,545     24.3 (23.9 - 24.8) 5.9 (5.6 - 6.3) 59,478 25.6 (25.2 - 25.9) 6.6 (6.3 - 6.8) -1.3 -0.7 <0.01 <0.01
Women 23,234     26.9 (26.3 - 27.5) 7.5 (7.1 - 8.0) 36,750 27.4 (26.9 - 27.9) 7.6 (7.3 - 8.0) -0.5 -0.1 <0.01 <0.01
Persons 57,779     25.3 (25.0 - 25.7) 6.6 (6.3 - 6.8) 96,228 26.3 (26.0 - 26.6) 6.9 (6.7 - 7.1) -1.0 -0.3 <0.01 <0.01
Oesophagus Men 6,108       29.4 (28.2 - 30.6) 7.4 (6.5 - 8.3) 13,909 34.1 (33.3 - 34.9) 8.8 (8.1 - 9.4) -4.7 -1.4 <0.01 <0.01
Women 3,802       32.0 (30.4 - 33.6) 8.9 (7.4 - 10.5) 8,213 34.7 (33.6 - 35.8) 11.6 (10.6 - 12.6) -2.7 -2.7 <0.01 <0.01
Persons 9,910       30.1 (29.2 - 31.0) 8.0 (7.3 - 8.8) 22,122 34.1 (33.4 - 34.7) 9.7 (9.2 - 10.3) -4.0 -1.7 <0.01 <0.01
Ovary Women 8,655       66.0 (65.0 - 66.9) 39.2 (38.8 - 40.5) 20,851 68.0 (67.4 - 68.6) 37.9 (37.1 - 38.7) -2.0 +1.3 <0.01 0.082
Prostate Men 37,335     90.0 (89.6 - 90.4) 69.2 (68.2 - 70.2) 96,451 90.6 (90.4 - 90.9) 71.1 (70.5 - 71.6) -0.6 -1.9 <0.01 <0.01
Rectum Men 11,925     72.3 (71.4 - 73.2) 46.6 (45.2 - 48.1) 24,111 76.0 (75.4 - 76.6) 50.8 (49.8 - 51.7) -3.7 -4.2 <0.01 <0.01
Women 7,715       75.0 (74.0 - 76.0) 50.1 (48.5 - 51.7) 16,863 77.2 (76.5 - 77.8) 53.7 (52.6 - 54.7) -2.2 -3.6 <0.01 <0.01
Persons 19,640     73.2 (72.6 - 73.9) 47.7 (46.7 - 48.8) 40,974 76.4 (76.0 - 76.8) 52.1 (51.4 - 52.8) -3.2 -4.4 <0.01 <0.01
Stomach Men 9,525       33.8 (32.8 - 34.8) 12.6 (11.6 - 13.5) 16,217 36.6 (35.9 - 37.4) 13.0 (12.3 - 13.7) -2.8 -0.4 <0.01 0.021
Women 5,241       35.2 (33.8 - 36.6) 14.8 (13.5 - 16.2) 8,534 37.7 (36.6 - 38.8) 16.3 (15.3 - 17.4) -2.5 -1.5 <0.01 0.021
Persons 14,766     34.4 (33.6 - 35.1) 13.3 (12.5 - 14.0) 24,751 36.9 (36.3 - 37.5) 14.2 (13.6 - 14.7) -2.5 -0.9 <0.01 0.021
1 Cancer survival varies with age at diagnosis, so the survival rates for all ages (15-99 years) have been age-standardised to control for differences in the age profile of cancer patients between geographical areas (see text).
2 Aged 15-99 years at diagnosis.
3 On 19 November 2004, the Department of Health named the 88 most health-deprived Primary Care Trusts (PCTs) in England included in the 'Spearhead' Group.
4 All other Primary Care Trusts (PCTs) in England not included in the 'Spearhead' Group.
5  See table in the worksheet 'ICD site codes' for the International Classification of Diseases, Tenth Revision (ICD-10) codes used for cancers diagnosed from 1998 to 2003.
6 Adult patients diagnosed with one of 10 common cancers during 1998-2003 in 'Spearhead' PCTs and the rest of England and followed up to the end of 2004.
8 The difference (in percentage points) between the relative survival for patients resident in 'Spearhead' PCTs and in the rest of England.
9 95% confidence interval.
Table 1: One- and five-year age-standardised1 relative survival (%) for adult2 patients diagnosed during 1998-2003, 10 common cancers, by sex: 'Spearhead' 
Primary Care Trusts (PCTs)3 and Rest of England4
7 Eligible patients included in the survival analysis; for exclusion criteria see Coleman MP et al (1999) Cancer Survival Trends in England and Wales 1971-1995: deprivation and NHS Region. Studies on Medical and Population Subjects No.61. London: The 
Stationery Office.
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 Patients diagnosed 1998-20036
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patients7
One-year relative survival Five-year relative survival Number of
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95% CI9 95% CI9
One-year relative survival Five-year relative survival Difference8
Significance (p-value) of 
difference
International Classification of Diseases (ICD) Tenth Revision codes for selected cancers
Cancer ICD-10 codes
Bladder C67
Breast C50
Cervix C53
Colon C18
Lung C33, C34
Oesophagus C15
Ovary C56
Prostate C61
Rectum C19 - C20
Stomach C16
Five-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
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One-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
England, bladder cancer, patients diagnosed during 1998-2003 and followed up to 2004
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One-year and five-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
England, breast cancer, women diagnosed during 1998-2003 & followed up to 2004 
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One-year and five-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
England, cancer of the cervix, women diagnosed during 1998-2003 and followed up to 2004
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Five-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
England, colon cancer, patients diagnosed during 1998-2003 and followed up to 2004 
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One-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
England, lung cancer, patients diagnosed during 1998-2003 and followed up to 2004
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Five-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
England, lung cancer, patients diagnosed during 1998-2003 and followed up to 2004 
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One-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
England, cancer of the oesophagus, patients diagnosed during 1998-2003 and followed up to 2004 
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Five-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
England, cancer of the oesophagus, patients diagnosed during 1998-2003 and followed up to 2004 
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One-year and five-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
England, ovarian cancer, women diagnosed during 1998-2003 and followed up to 2004  
66.0 68.0
39.2 37.9
0
10
20
30
40
50
60
70
80
90
100
Spearhead (1 year) Rest of England (1 year ) Spearhead (5 years) Rest of England (5 years)
R
e
l
a
t
i
v
e
 
S
u
r
v
i
v
a
l
 
%
One-year and five-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
England, prostate cancer, men diagnosed during 1998-2003 and followed up to 2004  
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One-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
England, rectal cancer, patients diagnosed in 1998-2003 and followed up to 2004 
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Five-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
England, rectal cancer, patients diagnosed during 1998-2003 and followed up to 2004 
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One-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
England, stomach cancer, patients diagnosed in 1998-2003 and followed up to 2004  
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Five-year relative survival (%) with 95% confidence intervals, 'Spearhead' PCTs and all other PCTs: 
England, stomach cancer, patients diagnosed during 1998-2003 and followed up to 2004
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For labels in graphs only:
Cancer Sex Year Cases Deaths RS RS_lo RS_hi Cases Deaths RS RS_lo RS_hi Spearhead (men)
Rest of England (men)
bladder Males One 10,789 5,316 77.31 76.46 78.17 24,778 11,922 78.84 78.30 79.39 0.000
Five 57.05 55.64 58.47 60.41 59.53 61.29 0.000 Spearhead (women)
Females One 4,513 2,623 66.35 64.89 67.80 9,337 5,266 70.38 69.40 71.37 0.000 Rest of England (women)
Five 49.06 47.16 50.96 53.63 52.28 54.99 0.000
Persons One 15,302 7,939 73.91 73.18 74.64 34,115 17,188 76.38 75.91 76.86 0.000 Spearhead (persons)
Five 54.97 53.85 56.10 58.58 57.85 59.31 0.000 Rest of England (persons)
breast Females One 54,019 12,540 93.45 93.21 93.69 136,340 29,304 94.19 94.05 94.34 0.000
Five 78.17 77.61 78.73 79.75 79.41 80.09 0.000 Spearhead (1 year) 
Rest of England (1 year )
cervix Females One 5,049 1,707 81.40 80.31 82.49 8,639 2,890 82.17 81.30 83.03 0.281
Five 63.35 61.79 64.90 62.67 61.42 63.93 0.509 Spearhead (5 years)
Rest of England (5 years)
colon Males One 13,828 7,680 66.10 65.24 66.95 32,813 17,690 69.28 68.75 69.82 0.000
Five 47.14 45.81 48.47 48.32 47.49 49.15 0.000
Females One 13,062 7,334 65.86 65.02 66.70 32,585 17,532 68.94 68.43 69.46 0.000
Five 47.91 46.73 49.10 49.62 48.87 50.36 0.000
Persons One 26,890 15,014 65.91 65.31 66.50 65,398 35,222 68.99 68.62 69.35 0.000
Five 47.41 46.54 48.27 48.92 48.37 49.46 0.000
lung Males One 34,545 31,848 24.33 23.87 24.80 59,478 54,662 25.58 25.21 25.94 0.000
Five 5.93 5.59 6.27 6.57 6.30 6.83 0.003
Females One 23,234 21,009 26.88 26.29 27.47 36,750 33,111 27.42 26.93 27.90 0.000
Five 7.52 7.07 7.97 7.65 7.27 8.02 0.003
Persons One 57,779 52,857 25.33 24.96 25.69 96,228 87,773 26.27 25.97 26.56 0.000
Five 6.56 6.29 6.83 6.87 6.65 7.09 0.003
oesophagus Males One 6,108 5,413 29.42 28.25 30.59 13,909 12,079 34.07 33.27 34.87 0.000
Five 7.41 6.50 8.33 8.77 8.13 9.41 0.000
Females One 3,802 3,385 32.03 30.43 33.63 8,213 7,269 34.68 33.55 35.82 0.000
Five 8.94 7.43 10.45 11.59 10.60 12.58 0.000
Persons One 9,910 8,798 30.09 29.17 31.00 22,122 19,348 34.07 33.43 34.71 0.000
Five 8.02 7.28 8.77 9.71 9.17 10.25 0.000
ovary Females One 8,655 4,882 65.95 64.99 66.91 20,851 12,139 67.96 67.36 68.56 0.000
Five 39.23 37.97 40.49 37.91 37.10 38.71 0.082
prostate Males One 37,335 13,202 89.98 89.57 90.38 96,451 31,557 90.64 90.40 90.89 0.005
Five 69.20 68.21 70.20 71.05 70.47 71.63 0.002
rectum Males One 11,925 6,298 72.32 71.44 73.20 24,111 11,927 75.97 75.39 76.56 0.000
Five 46.64 45.22 48.05 50.77 49.81 51.74 0.000
Females One 7,715 3,990 74.99 73.98 75.99 16,863 8,208 77.19 76.53 77.85 0.000
Five 50.09 48.53 51.66 53.68 52.64 54.72 0.000
Persons One 19,640 10,288 73.21 72.56 73.87 40,974 20,135 76.40 75.97 76.83 0.000
Five 47.74 46.72 48.77 52.12 51.42 52.82 0.000
stomach Males One 9,525 8,101 33.80 32.84 34.76 16,217 13,733 36.60 35.85 37.36 0.000
Five 12.56 11.63 13.50 13.02 12.32 13.73 0.021
Females One 5,241 4,433 35.23 33.85 36.61 8,534 7,200 37.69 36.57 38.80 0.000
Five 14.84 13.49 16.19 16.35 15.25 17.45 0.021
Persons One 14,766 12,534 34.35 33.57 35.13 24,751 20,933 36.88 36.27 37.50 0.000
Five 13.26 12.52 14.00 14.15 13.57 14.74 0.021
Significance (p-value) of 
difference in survivalRest of EnglandSpearhead PCTs
Cancer patients diagnosed in England in 1998-2003, followed up to 2004; Relative survival using complete approach, regional life tables
